R & D- medical: biomedical (basic research)
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $679,923
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $679,923.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $679,923 |
About this award
This is a federal contract award from the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Weill Medical College of Cornell University, a private research university. The $679,923 firm-fixed-price contract is a delivery order under the NCI's larger "PREVENT Cancer Program (PREVENT)" indefinite delivery contract, which has a ceiling value of $149,995,000. The contract is for research and development in biomedical basic research related to preclinical cancer prevention.
Weill Medical College is performing the work, which includes preclinical efficacy testing and developing intermediate endpoint biomarkers for cancer preventive agents. The contract does not have a set-aside designation. Weill Medical College has also subcontracted portions of the work to the German Cancer Research Center (DKFZ) and Columbia University. These subcontractors are providing specialized services like identifying tumor-associated mutations, evaluating immunogenicity of vaccine candidates, and testing preventive agents in preclinical models of gastrointestinal cancers.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 24, 2015.
How much is contract HHSN26100002 worth?
The government has obligated $679,923 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201500039I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award